NCT00015652View on ClinicalTrials.gov

Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

March 31, 2005

Conditions

HIV InfectionsHepatitis C

Interventions

DRUG

Ribavirin

DRUG

Aldesleukin

DRUG

Peginterferon alfa-2b

Trial Locations (8)

10021

Weill Med. College of Cornell Univ., The Cornell CTU, New York

21287

Johns Hopkins Adult AIDS CRS, Baltimore

52242

Univ. of Iowa Healthcare, Div. of Infectious Diseases, Iowa City

60611

Northwestern University CRS, Chicago

75390

Univ. of Texas Southwestern Med. Ctr., Amelia Court Continuity Clinic, Dallas

90095

UCLA CARE Center CRS, Los Angeles

452670405

Univ. of Cincinnati CRS, Cincinnati

Unknown

University of Colorado Hospital CRS, Aurora

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00015652 - Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection | Biotech Hunter | Biotech Hunter